1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Baker Bros. Advisors Lp Buys MyoKardia Inc, Neurocrine Biosciences Inc, Audentes Therapeutics Inc, Sells Spark Therapeutics Inc, Array BioPharma Inc, Solid Biosciences Inc

New York, NY, based Investment company Baker Bros. Advisors Lp buys MyoKardia Inc, Neurocrine Biosciences Inc, Audentes Therapeutics Inc, Axsome Therapeutics Inc, Dermira Inc, Macrogenics Inc, Acorda Therapeutics Inc, Protagonist Therapeutics Inc, Apellis Pharmaceuticals Inc, CytomX Therapeutics Inc, La Jolla Pharmaceutical Co, sells Spark Therapeutics Inc, Array BioPharma Inc, Solid Biosciences Inc, Novavax Inc, Abeona Therapeutics Inc, ContraFect Corp, Aevi Genomic Medicine Inc, Proteon Therapeutics Inc during the 3-months ended 2019Q1, according to the most recent filings of the investment company, Baker Bros. Advisors Lp. As of 2019Q1, Baker Bros. Advisors Lp owns 91 stocks with a total value of $15.5 billion. These are the details of the buys and sells.

For the details of BAKER BROS. ADVISORS LP's stock buys and sells, go to https://www.gurufocus.com/guru/baker+bros.+advisors+lp/current-portfolio/portfolio

These are the top 5 holdings of BAKER BROS. ADVISORS LP
  1. Seattle Genetics Inc (SGEN) - 51,049,760 shares, 24.17% of the total portfolio. Shares added by 0.01%
  2. Incyte Corp (INCY) - 34,271,827 shares, 19.05% of the total portfolio. Shares added by 0.06%
  3. BeiGene Ltd (BGNE) - 11,959,824 shares, 10.20% of the total portfolio.
  4. Alexion Pharmaceuticals Inc (ALXN) - 8,558,068 shares, 7.48% of the total portfolio. Shares added by 0.03%
  5. ACADIA Pharmaceuticals Inc (ACAD) - 39,713,842 shares, 6.89% of the total portfolio.
New Purchase: Axsome Therapeutics Inc (AXSM)

Baker Bros. Advisors Lp initiated holding in Axsome Therapeutics Inc. The purchase prices were between $2.63 and $16.34, with an estimated average price of $9.17. The stock is now traded at around $23.00. The impact to a portfolio due to this purchase was 0.11%. The holding were 1,200,000 shares as of .

New Purchase: Dermira Inc (DERM)

Baker Bros. Advisors Lp initiated holding in Dermira Inc. The purchase prices were between $6.19 and $14.13, with an estimated average price of $8.29. The stock is now traded at around $10.31. The impact to a portfolio due to this purchase was 0.08%. The holding were 906,943 shares as of .

New Purchase: Macrogenics Inc (MGNX)

Baker Bros. Advisors Lp initiated holding in Macrogenics Inc. The purchase prices were between $11.11 and $25.6, with an estimated average price of $17.21. The stock is now traded at around $16.27. The impact to a portfolio due to this purchase was 0.04%. The holding were 302,600 shares as of .

New Purchase: Protagonist Therapeutics Inc (PTGX)

Baker Bros. Advisors Lp initiated holding in Protagonist Therapeutics Inc. The purchase prices were between $6.5 and $13.77, with an estimated average price of $8.76. The stock is now traded at around $10.80. The impact to a portfolio due to this purchase was 0.03%. The holding were 403,893 shares as of .

New Purchase: Acorda Therapeutics Inc (ACOR)

Baker Bros. Advisors Lp initiated holding in Acorda Therapeutics Inc. The purchase prices were between $12.93 and $17.47, with an estimated average price of $15.03. The stock is now traded at around $11.28. The impact to a portfolio due to this purchase was 0.03%. The holding were 292,134 shares as of .

New Purchase: CytomX Therapeutics Inc (CTMX)

Baker Bros. Advisors Lp initiated holding in CytomX Therapeutics Inc. The purchase prices were between $9.5 and $19.16, with an estimated average price of $14.88. The stock is now traded at around $10.86. The impact to a portfolio due to this purchase was 0.01%. The holding were 194,377 shares as of .

Added: MyoKardia Inc (MYOK)

Baker Bros. Advisors Lp added to a holding in MyoKardia Inc by 222.39%. The purchase prices were between $39.23 and $55.82, with an estimated average price of $46.05. The stock is now traded at around $47.52. The impact to a portfolio due to this purchase was 0.23%. The holding were 1,016,306 shares as of .

Added: Neurocrine Biosciences Inc (NBIX)

Baker Bros. Advisors Lp added to a holding in Neurocrine Biosciences Inc by 50.43%. The purchase prices were between $69.31 and $91.53, with an estimated average price of $83.53. The stock is now traded at around $78.89. The impact to a portfolio due to this purchase was 0.21%. The holding were 1,098,670 shares as of .

Added: Audentes Therapeutics Inc (BOLD)

Baker Bros. Advisors Lp added to a holding in Audentes Therapeutics Inc by 88.39%. The purchase prices were between $21.32 and $39.54, with an estimated average price of $28.43. The stock is now traded at around $38.23. The impact to a portfolio due to this purchase was 0.2%. The holding were 1,715,183 shares as of .

Added: Apellis Pharmaceuticals Inc (APLS)

Baker Bros. Advisors Lp added to a holding in Apellis Pharmaceuticals Inc by 60.00%. The purchase prices were between $12.81 and $19.82, with an estimated average price of $15.64. The stock is now traded at around $18.93. The impact to a portfolio due to this purchase was 0.02%. The holding were 313,725 shares as of .

Added: La Jolla Pharmaceutical Co (LJPC)

Baker Bros. Advisors Lp added to a holding in La Jolla Pharmaceutical Co by 226.65%. The purchase prices were between $5.24 and $10.52, with an estimated average price of $6.55. The stock is now traded at around $6.57. The impact to a portfolio due to this purchase was 0.01%. The holding were 505,240 shares as of .

Sold Out: Solid Biosciences Inc (SLDB)

Baker Bros. Advisors Lp sold out a holding in Solid Biosciences Inc. The sale prices were between $7.19 and $32.37, with an estimated average price of $16.87.

Sold Out: Novavax Inc (NVAX)

Baker Bros. Advisors Lp sold out a holding in Novavax Inc. The sale prices were between $10.18 and $46.8, with an estimated average price of $31.97.

Sold Out: Aevi Genomic Medicine Inc (GNMX)

Baker Bros. Advisors Lp sold out a holding in Aevi Genomic Medicine Inc. The sale prices were between $0.19 and $0.77, with an estimated average price of $0.23.

Sold Out: Proteon Therapeutics Inc (PRTO)

Baker Bros. Advisors Lp sold out a holding in Proteon Therapeutics Inc. The sale prices were between $0.5 and $3.75, with an estimated average price of $2.84.



Here is the complete portfolio of BAKER BROS. ADVISORS LP. Also check out:

1. BAKER BROS. ADVISORS LP's Undervalued Stocks
2. BAKER BROS. ADVISORS LP's Top Growth Companies, and
3. BAKER BROS. ADVISORS LP's High Yield stocks
4. Stocks that BAKER BROS. ADVISORS LP keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK